AngioDynamics Posts Record FY2026 Revenue, 18% Med Tech Growth, and Issues FY2027 Outlook
ANGO sits 64% above its 52-week low of $8.36.
Summary
AngioDynamics delivered record FY2026 revenue of $320.2M (+9.4% pro forma), with Med Tech up 18.4%, achieved positive adjusted EBITDA, and guided FY2027 revenue to $336–$341M, projecting continued Med Tech growth and stable margins.
Key Events · Earnings and Guidance · ANGO
-
Record FY2026 Revenue
Pro forma net sales reached $320.2 million, a 9.4% year-over-year increase, as the Med Tech segment surged 18.4% to $150.0 million and Med Device rose 2.5% to $170.2 million.
-
Profitability Milestone
Full-year adjusted EBITDA turned positive at $13.2 million, and the company generated $3.1 million in cash from operations, ending the period with $53.9 million in cash and no debt.
-
FY2027 Guidance Issued
Management expects net sales of $336–$341 million, Med Tech growth of 12–15%, flat Med Device sales, gross margin of 54–55%, and adjusted EBITDA of $13–$16 million.
-
Clinical & Regulatory Catalysts
The FDA approved the IDE for the RELIEF study evaluating NanoKnife for BPH; two-year PRESERVE data demonstrated durable prostate cancer outcomes; and Medicare LCD and CPT codes now cover NanoKnife in prostate and liver procedures.
Analysis · ANGO · Industrial Applications And Services
A record fiscal 2026 saw pro forma revenue climb 9.4% to $320.2 million, fueled by an 18.4% surge in the higher-margin Med Tech segment. The company reached a critical inflection point with positive adjusted EBITDA of $13.2 million and $3.1 million in operating cash flow, signaling a shift toward self-funding operations. Looking ahead, FY2027 guidance targets total revenue of $336–$341 million—a 5–6% increase—with Med Tech expanding 12–15% and gross margins holding steady at 54–55%. While the bottom line remains GAAP-negative with an adjusted loss per share of $0.24, the results and outlook underscore the strategic pivot to faster-growing, higher-margin platforms. A series of clinical and regulatory catalysts—including FDA IDE approvals for the RELIEF, APEX-Return, and PAVE studies, plus Medicare coverage for NanoKnife—further strengthen the pipeline for sustained Med Tech momentum.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANGO was trading at $13.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $527.8M. The 52-week trading range was $8.36 to $13.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.